RESUMO
BACKGROUND: The WHO European Region (EUR) has adopted the goal of eliminating measles and rubella but individual countries perform differently in achieving this goal. Measles virus spread across the EUR by mobile groups has recently led to large outbreaks in the insufficiently vaccinated resident population. As an instrument for monitoring the elimination process and verifying the interruption of endemic virus transmission, molecular surveillance has to provide valid and representative data. Irrespective of the country's specific situation, it is required to ensure the functionality of the laboratory surveillance that is supported by the WHO Global Measles and Rubella Laboratory Network. AIMS: To investigate whether the molecular surveillance in the EUR is adequate for the challenges in the elimination phase, we addressed the quality assurance of molecular data, the continuity and intensity of molecular monitoring, and the analysis of transmission chains. SOURCES: Published articles, the molecular External Quality Assessment Programme of the WHO, the Centralized Information System for Infectious Diseases of the WHO EUR and the WHO Measles and Rubella Nucleotide Surveillance databases served as information sources. CONTENT: Molecular proficiency testing conducted by the WHO in 2016 has shown that the expertise for measles and rubella virus genotyping exists in all parts of the EUR. The analysis of surveillance data reported nationally to the WHO in 2013-2016 has revealed some countries with outbreaks but not sufficiently representative molecular data. Long-lasting supranational MV transmission chains were identified. IMPLICATIONS: A more systematic molecular monitoring and recording of the transmission pattern for the whole EUR could help to create a meaningful picture of the elimination process.
Assuntos
Monitoramento Epidemiológico , Vírus do Sarampo/isolamento & purificação , Sarampo/epidemiologia , Vírus da Rubéola/isolamento & purificação , Rubéola (Sarampo Alemão)/epidemiologia , Surtos de Doenças , Transmissão de Doença Infecciosa , Europa (Continente)/epidemiologia , Técnicas de Genotipagem/métodos , Técnicas de Genotipagem/normas , Humanos , Ensaio de Proficiência Laboratorial , Sarampo/transmissão , Vírus do Sarampo/classificação , Vírus do Sarampo/genética , Epidemiologia Molecular/métodos , Epidemiologia Molecular/normas , Rubéola (Sarampo Alemão)/transmissão , Vírus da Rubéola/classificação , Vírus da Rubéola/genética , Organização Mundial da SaúdeRESUMO
Globally measles remains one of the leading causes of death among young children even though a safe and cost-effective vaccine is available. The World Health Organization (WHO) European Region has seen a decline in measles and rubella cases in recent years. The recent outbreaks have primarily affected adolescents and young adults with no vaccination or an incomplete vaccination history. Eliminating measles and rubella is one of the top immunization priorities of the European Region as outlined in the European Vaccine Action Plan 2015-2020. Following the 2010 decision by the Member States in the Region to initiate the process of verifying elimination, the European Regional Verification Commission for Measles and Rubella Elimination (RVC) was established in 2011. The RVC meets every year to evaluate the status of measles and rubella elimination in the Region based on documentation submitted by each country's National Verification Committees. The verification process was however modified in late 2014 to assess the elimination status at the individual country level instead of at regional level. The WHO European Region has made substantial progress towards measles and rubella elimination over the past 5 years. The RVC's conclusion in 2016 that 70% and 66% of the 53 Member States in the Region had interrupted the endemic transmission of measles and rubella, respectively, by 2015 is a testament to this progress. Nevertheless, where measles and rubella remain endemic, challenges in vaccination service delivery and disease surveillance will need to be addressed through focused technical assistance from WHO and development partners.
Assuntos
Erradicação de Doenças/organização & administração , Sarampo/epidemiologia , Sarampo/prevenção & controle , Rubéola (Sarampo Alemão)/epidemiologia , Rubéola (Sarampo Alemão)/prevenção & controle , Erradicação de Doenças/tendências , Europa (Continente)/epidemiologia , Humanos , Organização Mundial da SaúdeRESUMO
Measles and rubella persist in the World Health Organization European Region despite long-standing and widespread use of vaccines against them. Our aim was to review the epidemiology of measles and rubella in relation to the goal of eliminating these diseases from the Region by 2015. We report on the number of measles and rubella cases by country in 2012 and present an analysis of preliminary measles and rubella surveillance data for 2013. We analysed data of these diseases for 2013 by age group, diagnosis confirmation (clinical, laboratory-confirmed and epidemiologically linked), and vaccination, hospitalization and importation status. We also report on measles-related deaths. For 2012, there were 26,785 [corrected] measles cases and 29,601 rubella cases reported in the Region. For 2013, these figures were 31,520 and 39,367 respectively. Most measles cases in 2013 (96%; n = 30,178) were reported by nine countries: Georgia (7830), Germany (1773), Italy (2216), the Netherlands (2499), Romania (1074), the Russian Federation (2174), Turkey (7404), Ukraine (3308) and the United Kingdom (1900). In 2013, most measles cases were among unvaccinated persons and over one in three patients were aged 20 years and older. For 2013, almost all rubella cases were reported by Poland (n = 38,585; 98%). High population immunity and high-quality surveillance are the cornerstones to eliminate measles and rubella. Without sustained political commitment and accelerated action by Member States and partners, the elimination of measles and rubella in the WHO European Region may not be achieved.
Assuntos
Surtos de Doenças/prevenção & controle , Sarampo/epidemiologia , Rubéola (Sarampo Alemão)/epidemiologia , Europa (Continente)/epidemiologia , Humanos , Vacinação , Organização Mundial da SaúdeRESUMO
Substantial progress has been made in the World Health Organization (WHO) European Region toward reaching the goal of measles and rubella elimination. We analyzed the surveillance data of 2012 on measles and rubella for age-group, diagnosis confirmation status (clinical, laboratory-confirmed and epidemiologically linked), vaccination status, and measles-related deaths. For 2012, there were 23,871 measles cases and 29,361 rubella cases reported in the region, mostly among unvaccinated persons. Almost one in three patients with measles and one in five patients with rubella were aged 20 years and older. In a few countries, widespread outbreaks or indigenous transmission of measles persisted in 2012. While most countries in the region have controlled rubella, a small number still reported a high incidence and several outbreaks. Therefore, more efforts are required to achieve the goal of eliminating measles and rubella in the WHO European Region by 2015, particularly in high-incidence countries. The WHO measles and rubella elimination plan stipulates that all countries should achieve and maintain the required high vaccination coverage while conducting high-quality surveillance.
Assuntos
Surtos de Doenças/prevenção & controle , Surtos de Doenças/estatística & dados numéricos , Sarampo/epidemiologia , Sarampo/prevenção & controle , Rubéola (Sarampo Alemão)/epidemiologia , Rubéola (Sarampo Alemão)/prevenção & controle , Vacinação/estatística & dados numéricos , Distribuição por Idade , Europa (Continente)/epidemiologia , Alemanha/epidemiologia , Humanos , Incidência , Vacina contra Sarampo/uso terapêutico , Medição de Risco , Vacina contra Rubéola/uso terapêutico , Distribuição por Sexo , Organização Mundial da SaúdeRESUMO
We report an outbreak of measles that has been ongoing in the district of Neamt, Romania, since 22 August 2010. As of 21 September, 17 of 21 suspected cases have been laboratory-confirmed and there was one measles-related fatality.
Assuntos
Surtos de Doenças , Vacina contra Sarampo/administração & dosagem , Sarampo/epidemiologia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Masculino , Sarampo/prevenção & controle , Vigilância da População , Romênia/epidemiologia , Vacinação/estatística & dados numéricosRESUMO
Since early 2008, France has been experiencing a measles outbreak with almost 5,000 notified cases as of 30 June 2010, including three measles-related deaths. The proportion of cases 20 years or older reached 38% during the first half of 2010. This situation is the consequence of insufficient vaccine coverage (90% at age 24 months in 2007) that led to the accumulation of susceptibles over the last years. It underlines the need for additional measures targeting susceptible children and young adults.
Assuntos
Surtos de Doenças , Sarampo/epidemiologia , Adolescente , Adulto , Anticorpos Antivirais/sangue , Criança , Pré-Escolar , Feminino , França/epidemiologia , Genótipo , Humanos , Esquemas de Imunização , Incidência , Lactente , Masculino , Sarampo/prevenção & controle , Sarampo/virologia , Vírus do Sarampo/genética , Vírus do Sarampo/imunologia , Vírus do Sarampo/isolamento & purificação , Vacina contra Sarampo-Caxumba-Rubéola , Instituições Acadêmicas , Migrantes , Vacinação/estatística & dados numéricos , Populações Vulneráveis , Adulto JovemRESUMO
The first pneumococcal vaccine targeting the youngest age groups, a seven-valent conjugate vaccine (PCV7), was licensed in Europe in 2001. Since then several European countries have introduced PCV7 in their childhood vaccination schedules.Still, information on vaccination schemes, vaccine uptake and impact of vaccine introduction is scarce in Europe. The following article summarises the characteristics of national pneumococcal vaccination programmes for children in 32 European countries and provides an estimate of vaccine use based on sales data for 22 countries between 2001 and 2007. There were wide variations in the recommended PCV7 vaccination schemes and in PCV7 use.High vaccine uptake was not always related to the presence of a national vaccination programme.
Assuntos
Vacinas Pneumocócicas , Pré-Escolar , Europa (Continente) , Vacina Pneumocócica Conjugada Heptavalente , Humanos , Lactente , Vacinação/estatística & dados numéricosRESUMO
We report an outbreak of measles in Croatia, involving 49 cases with onset of symptoms between end of April and June 2008. Cases occurred in Zagreb and Slavonski Brod but investigations indicated a common epidemiological link between these two geographically separate regions.
Assuntos
Surtos de Doenças/estatística & dados numéricos , Sarampo/epidemiologia , Vigilância da População , Medição de Risco/métodos , Croácia/epidemiologia , Humanos , Incidência , Fatores de RiscoRESUMO
Earlier this year, an outbreak of measles was detected in Bulgaria, following an eight-year period without indigenous measles transmission, and continues to spread in the country. By the end of 48 week of 2009 (first week of November), 957 measles cases had been recorded. Most cases are identified among the Roma community living in the north-eastern part of the country. Measles has affected infants, children and young adults. The vaccination campaign that started earlier in the year in the affected administrative regions continues, targeting all individuals from 13 months to 30 years of age who have not received the complete two-dose regimen of the combined measles-mumps-rubella (MMR) vaccination.
Assuntos
Surtos de Doenças/prevenção & controle , Sarampo/epidemiologia , Sarampo/prevenção & controle , Adolescente , Adulto , Bulgária/epidemiologia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Vacina contra Sarampo/uso terapêutico , Fatores de Risco , Vacinação/tendências , Adulto JovemAssuntos
Surtos de Doenças , Rubéola (Sarampo Alemão)/epidemiologia , Adolescente , Adulto , Anticorpos Antivirais/análise , Anticorpos Antivirais/sangue , Anticorpos Antivirais/imunologia , Feminino , Humanos , Masculino , Malta/epidemiologia , Vigilância da População , Rubéola (Sarampo Alemão)/imunologia , Rubéola (Sarampo Alemão)/prevenção & controle , Vacina contra Rubéola/uso terapêuticoAssuntos
Surtos de Doenças/estatística & dados numéricos , Sarampo/epidemiologia , Vigilância da População , Medição de Risco/métodos , Viagem/estatística & dados numéricos , Adulto , Análise por Conglomerados , Dinamarca/epidemiologia , Feminino , Humanos , Incidência , Lactente , Masculino , Fatores de RiscoAssuntos
Surtos de Doenças/estatística & dados numéricos , Sarampo/epidemiologia , Vigilância da População , Medição de Risco/métodos , Adolescente , Adulto , Criança , Pré-Escolar , Dinamarca/epidemiologia , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Suécia/epidemiologia , População Urbana/estatística & dados numéricosRESUMO
A total of 17 928 measles cases were reported to EUVAC.NET in 2001-02, with a 41% increase between the 2 years, giving a crude incidence of 2.36 and 3.37 per 100 000 population respectively. Most reported cases were aged 1-9 years. Outbreak related measles cases amounted to 18% of reported cases in 2001 and 20% in 2002. Less than 1% of cases were known to be imported in 2001 and 2002. Encephalitis as a severe complication was reported in 21 in 2001 and 6 cases 2002. One death attributed to measles was reported in 2001. The proportion of reported cases with known vaccination status increased from 56% of cases in 2001 to 72% in 2002. Overall, the proportion of reported measles cases that were unvaccinated rose from 50% in 2001 to 66% in 2002.